Premier Biomedical Anti-Cancer Antibody Outperforms Leading Multi-Billion Dollar Commercial Cancer Treatments in Initial Head-to-Head Testing at a Major University
Premier Biomedical, Inc. (OTCQB:BIEI) announced today the favorable results of initial multi-faceted mouse testing of their patent pending anti-cancer antibody versus commercially available competitive drugs. The Premier Biomedical antibody, PBI-5D3H5, demonstrated superiority based on tumor volume and mouse survivability.
View full press release